Yeungnam Univ J Med.  2007 Dec;24(2):232-242.

Trabeculectomy Using Mitomycin C in Aphakic and Pseudophakic Eyes

Affiliations
  • 1Department of Ophthalmology, College of Medicine, Yeungnam University, Daegu, Korea. sccha@med.yu.ac.kr

Abstract

BACKGROUND: The safety and efficacy of trabeculectomy with Mitomycin C (MMC) for surgical treatment in aphakic and pseudophaic eyes were retrospectively evaluated.
MATERIALS AND METHODS
The authors reviewed 51 eyes of 45 patients who had been followed up for at least 6 months after trabeculectomy using MMC for aphakic and pseudophakic eyes. The success rate and complications were analyzed. The success criteria included intraocular pressures of 21 mmHg or less with or without glaucoma medications and no loss of light perception. Surgical failure was defined as a postoperative loss of light perception in patients with preoperative vision better than light perception, additional glaucoma surgery, or phthisis bulbi in patients with preoperative vision of no light perception.
RESULTS
The average follow up period was 27.7 months and the intraocular pressure was controlled under 21 mmHg in 36 eyes of 51 (70.6%) after the procedure with or without medication for glaucoma. Using the Kaplan-Meier survival analysis, the cumulative success rate at the 3-, 6-, 12-, 24- and 36-month intervals were 98.0%, 94.1%, 91.9%, 83.4% and 75.5%, respectively. The complications observed were hyphema (4 eyes), serous choroidal detachment (4 eyes), hypotony (3 eyes), and endophthalmitis (1 eye).
CONCLUSION
Trabeculectomy using Mitomycin C for the treatment of aphakic and pseudophaic eyes was safe and effective.

Keyword

Aphakia; Pseudophakia; Trabeculectomy

MeSH Terms

Aphakia
Choroid
Endophthalmitis
Follow-Up Studies
Glaucoma
Humans
Hyphema
Intraocular Pressure
Mitomycin*
Pseudophakia
Retrospective Studies
Trabeculectomy*
Mitomycin
Full Text Links
  • YUJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr